Stay updated on Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial

Sign up to get notified when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest has been deleted.
    Difference
    1%
    Check dated 2025-07-04T03:49:10.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.8%
    Check dated 2025-06-19T19:36:17.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:09:07.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T05:52:02.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T13:50:02.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a new phase II open-label study of nivolumab combined with ipilimumab and bicalutamide for HER2-negative metastatic or unresectable breast cancer, with changes in the study's collaborators and revision number. The previous goal of the protocol has been removed, indicating a shift in focus.
    Difference
    50%
    Check dated 2025-04-16T01:46:08.000Z thumbnail image

Stay in the know with updates to Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab, Ipilimumab, Bicalutamide in HER2- Clinical Trial page.